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Background:  Inﬂuenza  vaccines  are  now  widely  used  to  reduce  the  burden  of  annual  epidemics  of  inﬂuenza
virus  infections.  Inﬂuenza  vaccine  effectiveness  (VE)  is monitored  annually  to determine  VE  against  each
season’s circulating  inﬂuenza  strains  in  different  groups  such  as children,  adults  and  the  elderly.  Few
prospective  surveillance  programs  are  available  to  evaluate  inﬂuenza  VE  against  medically  attended
illness  for  patients  of all ages  in the  United  States.
Methods: We  conducted  surveillance  of patients  with  acute  respiratory  illnesses  in 101  clinics  across
the US  during  three  consecutive  inﬂuenza  seasons.  We  analyzed  laboratory  testing  results  for  inﬂuenza
virus,  self-reported  vaccine  history,  and  patient  characteristics,  deﬁning  cases  as  patients  who  tested
positive  for  inﬂuenza  virus  and controls  as  patients  who  tested  negative  for inﬂuenza  virus.  Comparison
of  inﬂuenza  vaccination  coverage  among  cases  versus  controls,  adjusted  for potential  confounders,  was
used to estimate  VE  as one  minus  the adjusted  odds  ratio multiplied  by 100%.
Results:  We  included  10,650  patients  during  three  inﬂuenza  seasons  from  August  2010  through  December
2013,  and  estimated  inﬂuenza  VE  in children  6m–5y  of  age  (58%;  95%  CI: 49%–66%),  children  6–17y (45%;
95%  CI:  34%–53%),  adults  18–49y  (36%;  95%  CI: 24%,  46%),  and  adults  ≥50y  (34%, 95%  CI: 13%,  51%).  VE
was  higher  against  inﬂuenza  A(H1N1)  compared  to  A(H3N2)  and  B.
Conclusions:  Our  estimates  of  moderate  inﬂuenza  VE  conﬁrm  the  important  role  of  vaccination  in  pro-
tecting  against  medically  attended  inﬂuenza  virus  infection.
evierPublished  by  Els
. Introduction
Inﬂuenza vaccines are now widely used to reduce the burden
f annual epidemics of inﬂuenza virus infections. In the United
tates, universal vaccination recommendations were established
or all persons aged ≥6 months in 2010 [1]. Inﬂuenza vaccine effec-
iveness (VE) is monitored annually to determine VE against each
eason’s circulating inﬂuenza strains in different groups such as
hildren, adults and the elderly. One approach for monitoring VE
s a variant of the case-control study known as the test-negative
esign [2,3]. In this design, patients with acute respiratory illness
re identiﬁed in a clinical setting and tested for inﬂuenza virus.
est-positive patients are deﬁned as cases, while test-negative
atients are deﬁned as controls. The VE is then estimated by com-
aring the vaccination coverage of cases and controls, adjusting for
∗ Corresponding author at: MPH, 1600 Clifton Road, NE, Mailstop A-32, Atlanta,
A 30333, United States. Tel.: +1 404 639 4830.
E-mail address: AFowlkes@cdc.gov (A. Fowlkes).
ttp://dx.doi.org/10.1016/j.vaccine.2015.11.016
264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-N Ltd. This  is  an  open  access  article  under  the CC BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
potential confounders. The test-negative design is growing in pop-
ularity because of the ease of data collection in clinics, and because
the design explicitly accounts for health-care seeking behavior
which can bias estimates of VE in more traditional case con-
trol studies with community controls. Simulation studies have
demonstrated that the test-negative design can produce accurate
estimates of VE in various circumstances [4]. The earliest test-
negative studies were nested within existing routine surveillance
systems in Canada [5], while some more recent studies in the US
have been established for research purposes [6–8], and the study
design is now being used in many countries [9–12].
As research studies in the US can be very costly, we  evalu-
ated the feasibility of calculating inﬂuenza VE using data collected
through public health surveillance. In 2009 the US Centers for
Disease Control and Prevention (CDC) established the Inﬂuenza
Incidence Surveillance Project (IISP) as a sentinel surveillance net-
work to determine the community burden of consultations for
acute respiratory infections and inﬂuenza virus infections [13–15].
By collecting data on inﬂuenza vaccination status, this study also
permits estimation of VE using the test-negative approach. The
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Comparison of the characteristics of patients testing positive for any inﬂuenza virus
versus the patients testing negative for inﬂuenza virus, for the 10,650 patients
included during the three inﬂuenza seasons in our study period.
Characteristic Test-positive
(n = 3743) N (%)
Test-negative
(n = 6907) N (%)
Age group
6m–5y 685 (18.3%) 2039 (29.5%)
6–17y 1345 (35.9%) 1779 (25.8%)
18–49y 1372 (36.7%) 2427 (35.1%)
≥50y 338 (9.0%) 658 (9.5%)
Unknown 3 (0.1%) 4 (0.1%)
Sex
Male 1797 (48.0%) 3048 (44.1%)
Female 1914 (51.1%) 3800 (55.0%)
Unknown 32 (0.9%) 59 (0.9%)
Inﬂuenza vaccination history
Yes for that season (>2
weeks prior to illness
onset)
696 (18.6%) 2097 (30.4%)
No  reported
vaccination for that
season (>2 weeks
prior to illness onset)
2204 (58.9%) 3367 (48.7%)
Reported as unknown 843 (22.5%) 1443 (20.9%)
Inﬂuenza season
2010–11 1424 (38.0%) 2784 (40.3%)
2011–12 472 (12.6%) 1692 (24.5%)
2012–13 1847 (49.3%) 2431 (35.2%)2 B.J. Cowling et al. / 
bjectives of the present study were to assess VE overall, by cir-
ulating inﬂuenza strains, and by age, for the inﬂuenza seasons in
010–11, 2011–12 and 2012–13.
. Methods
.1. Subjects
This study involved patients attended by health care providers
articipating in surveillance to monitor acute respiratory infections
ARI) with laboratory conﬁrmation of inﬂuenza infection [13–15].
urveillance was conducted in 101 clinics under the supervision
f 13 public health jurisdictions for the following seasons: Florida,
owa, Minnesota, North Dakota, Oregon, Wisconsin, New York City;
ew Jersey, Virginia, Los Angeles county, and Philadelphia from
ugust 2010 to July 2013; Utah from October 2010 to July 2011;
exas from August 2011 through July 2013. Each site recruited clin-
cs that, in combination, represented patients of all ages. The IISP
ses routinely collected specimens and public health surveillance
ata.
Patients were evaluated by clinical staff to identify ARI with an
nset ≤7 days prior to consultation; ARI was deﬁned as reporting
t least 2 of the following symptoms: fever, cough, sore throat, rhi-
orrhea, and congestion. From the ﬁrst 10 ARI patients presenting
ach week, a nasopharyngeal, oropharyngeal or nasal swab was
ollected and placed in viral transport media for inﬂuenza testing.
election of patients for testing was not based on any provider deci-
ion. Demographic and clinical data were collected during the visit.
pecimens were tested by the state or local public health labora-
ory for inﬂuenza virus types A and B with subtyping of inﬂuenza A
H1N1)pdm09 and A(H3N2) using the CDC Human Inﬂuenza Virus
T-PCR Diagnostic Panel.
Inﬂuenza vaccination status in IISP was considered to be self-
eported, although each provider’s data collection methods varied,
epresenting a combination of self-report only (53 clinics), self-
eport with medical chart and registry veriﬁcation (17 clinics),
lectronic medical record extraction only (29 clinics), and vaccine
egistry only (2 clinics). A patient was considered vaccinated if
eceipt occurred >14 days prior to illness onset. The vaccine strains
or 2010–11, 2011–12 and 2012–13 are shown in Appendix Table
 [16–18].
.2. Ethical approval
The IISP uses routinely collected specimens and public health
urveillance data, and was therefore determined by CDC not to be
ubject to institutional review board approval for human research
rotections.
.3. Statistical analysis
Children aged <6 months were excluded from the present analy-
is since they are not recommended to receive inﬂuenza vaccine in
he US. Patients without inﬂuenza laboratory testing results were
lso excluded from analysis. We  used multiple imputation with
0 imputed data sets to allow for missing data on age, sex and
accination history [19]. Imputations were based on an additive
egression model which included age group, sex, state, calendar
eek, vaccination history, and the laboratory result for inﬂuenza
irus.
Inﬂuenza seasons were deﬁned as the period of consecu-
ive weeks with at least 10 inﬂuenza-positive patients, and we
estricted all of our analyses to inﬂuenza seasons. We  used con-
itional logistic regression models to estimate VE, conditioning by
eek of clinic visit, to account for changes in vaccine coverage over
alendar time. Regression models included age group, and sex tocontrol for their independent effects on the probability of inﬂuenza
infection in addition to their association with receipt of vaccination
that would otherwise confound the association between vacci-
nation and inﬂuenza. Inﬂuenza VE was  calculated as one minus
the conditional adjusted odds ratio of vaccination in test-positive
versus test-negative patients. Additional analyses were performed
for speciﬁc inﬂuenza types/subtypes (excluding specimens posi-
tive for inﬂuenza of other types/subtypes), and stratiﬁed by age and
season. In a sensitivity analysis we estimated VE on the subset of
the data with complete information on all covariates. To minimize
misclassiﬁcation bias, we  also estimated VE restricting analysis to
patients who had onset 0–4 days prior to consultation.
3. Results
From August 2010 through December 2013, 17,652 patients
were recruited, of whom 572 (3.2%) patients were not tested for
inﬂuenza virus. In addition, 397 (2.2%) patients were aged <6
months, and excluded. Of the remaining 16,683 patients, 3893
(23.3%) tested positive for inﬂuenza A or B virus. The inﬂuenza sea-
son in 2010–11 was a mixed season with circulation of A(H1N1),
A(H3N2) and B, while the season in 2011–12 was  dominated by
A(H3N2) and the season in 2012–13 was dominated by A(H3N2)
and B (Fig. 1). Vaccine strains (shown in Appendix Table 1)
were generally well matched to the prevalent strains each season
[16–18].
At least 10 test-positive patients per week were identiﬁed for 20,
17 and 23 consecutive weeks in 2010–11, 2011–12 and 2012–13
respectively (Fig. 1). The 10,650 patients included during the three
inﬂuenza seasons ranged in age from 6 months to 99 years, with
the majority made up of school-age children 6–17 years of age
and adults aged 18–49 years, while slightly less than half were
male (Table 1). All statistical analyses reported below were based
on these 10,650 patients. Inﬂuenza vaccination was reported for
30.4% of inﬂuenza test-negative patients, compared to 18.6% of
test-positive patients. Patient characteristics stratiﬁed by inﬂuenza
B.J. Cowling et al. / Vaccine 34 (2016) 61–66 63
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ith  inﬂuenza A(H1N1) and A(H3N2) or B are plotted as A(H1N1), while 11/16,683 
ype/subtype are shown in Appendix Table 2. Of the 10,650 patients,
0.8% reported a febrile illness.
Estimated VE for all inﬂuenza was 47% (95% conﬁdence interval,
I: 42%, 52%), ranging by season from 40% to 51%. We  found that
E was comparatively higher against inﬂuenza A(H1N1) compared
o inﬂuenza A(H3N2) and B. For any inﬂuenza virus, VE tended to
ecline as age increased, with point estimates ranging by age from
4% to 58% where conﬁdence intervals do not include zero (Table 2).
hile the sample size was insufﬁcient to condition by state and
eek of enrolment, very similar results were obtained when condi-ioning by state and month of enrolment (data not shown). Age and
eason-speciﬁc VE estimates by inﬂuenza type/subtype are shown
n Fig. 2. Point estimates of VE against all inﬂuenza fell in the range
2% to 63% each year, although robust estimation for adults aged
able 2
stimates of inﬂuenza vaccine effectiveness overall, and by age group and inﬂuenza type/s
easons  in our study period.
Analysis Inﬂuenza A(H1N1) Inﬂue
VE  (95% CI) VE (9
Imputed
dataseta
Age group
6m–5y 70% (48%, 83%) 60% 
6–17y 56% (31%, 72%) 33% 
18–49y 57% (39%, 70%) 26% 
≥50y −1% (−179%, 63%) 34% 
All  ages 63% (53%, 71%) 39% 
Inﬂuenza season
2010–11 55% (41%, 66%) 29% 
2011–12 79% (62%, 89%) 36% 
2012–13 70% (26%, 88%) 45% 
Restricted
analysisb
Age group
6m–5y 67% (41%, 81%) 61% 
6–17y 57% (32%, 73%) 32% 
18–49y 59% (39%, 72%) 24% 
≥50y −11% (−242%, 64%) 32% 
All  ages 63% (52%, 71%) 39% 
Inﬂuenza season
2010–11 55% (41%, 66%) 27% 
2011–12 78% (58%, 88%) 41% 
2012–13 76% (31%, 91%) 45% 
Complete
datasetc
Age group
6m–5y 78% (55%, 90%) 61% 
6–17y 58% (29%, 75%) 35% 
18–49y 75% (57%, 86%) 27% 
≥50y −21% (−305%, 64%) 30% 
All  ages 72% (61%, 79%) 40% 
Inﬂuenza season
2010–11 65% (50%, 76%) 28% 
2011–12 82% (65%, 90%) 40% 
2012–13 72% (18%, 90%) 45% 
a Missing data on age (n = 7), sex (n = 91) and vaccination history (n = 2286) were imput
xcluded from the estimation of VE for A(H1N1) and A(H3N2) but included in the overall
b 1297/10,650 (12.2%) patients were excluded who  with intervals between symptom o
c Including patients included during the three inﬂuenza seasons with complete data on
eable inﬂuenza A virus infections were excluded from the estimation of VE for A(H1N1)
*We adjusted in each regression model for age and sex, and conditioned by calendar wer inﬂuenza virus. A small number (4/16,683; 0.02%) of patients with co-infections
) patients with co-infections with inﬂuenza A(H3N2) and B are plotted as A(H3N2).
≥50 years was  not possible in 2010–11 due to low recruitment
in this age group. It was not possible to estimate age-speciﬁc VE
against inﬂuenza B in 2011–12 or against A(H1N1) in 2012–13 due
to low circulation during these years. Point estimates for VE in the
complete case analysis were very consistent with the estimates
in the main analysis that used multiple imputation to account for
missing data (Table 2).
4. DiscussionAcross three winters, we  estimated similar VE against med-
ically attended laboratory-conﬁrmed inﬂuenza in children and
adults with point estimates ranging from 34% to 58% (Table 2). We
found that VE was  higher against inﬂuenza A(H1N1) compared to
ubtype, 2010–13, based on the 10,650 patients included during the three inﬂuenza
nza A(H3N2) Inﬂuenza B Overall (Inﬂuenza A or B)
5% CI) VE (95% CI) VE (95% CI)
(47%, 69%) 51% (35%, 64%) 58% (49%, 66%)
(16%, 47%) 52% (40%, 62%) 45% (34%, 53%)
(8%, 41%) 33% (9%, 50%) 36% (24%, 46%)
(9%, 52%) 37% (−10%, 65%) 34% (13%, 51%)
(31%, 46%) 50% (43%, 57%) 47% (42%, 52%)
(12%, 44%) 40% (25%, 52%) 40% (30%, 48%)
(16%, 52%) 47% (2%, 71%) 50% (37%, 61%)
(35%, 53%) 58% (48%, 66%) 51% (43%, 57%)
(48%, 71%) 51% (32%, 64%) 58% (49%, 66%)
(14%, 46%) 53% (40%, 63%) 44% (33%, 53%)
(4%, 40%) 31% (5%, 50%) 36% (23%, 47%)
(3%, 53%) 36% (−19%, 66%) 34% (9%, 52%)
(31%, 47%) 50% (42%, 57%) 47% (42%, 52%)
(7%, 42%) 38% (22%, 51%) 39% (28%, 48%)
(20%, 56%) 46% (−1%, 71%) 52% (39%, 63%)
(34%, 54%) 59% (49%, 67%) 51% (44%, 58%)
(48%, 72%) 51% (30%, 66%) 60% (50%, 68%)
(17%, 50%) 54% (40%, 65%) 46% (35%, 56%)
(7%, 43%) 32% (4%, 52%) 39% (26%, 50%)
(1%, 51%) 34% (−21%, 64%) 33% (8%, 51%)
(31%, 48%) 51% (42%, 59%) 49% (43%, 54%)
(6%, 44%) 34% (13%, 51%) 40% (27%, 50%)
(18%, 56%) 44% (−8%, 71%) 54% (40%, 64%)
(34%, 54%) 59% (48%, 67%) 51% (43%, 58%)
ed. 73/10,650 (0.7%) patients with unsubtypeable inﬂuenza A virus infections were
 estimates.
nset to present more than 4 days, or with unknown onset date.
 age, sex and vaccination history (n = 8313). 57/8313(0.7%) patients with unsubty-
 and A(H3N2) but included in the overall estimates.
ek.
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nﬂuenza A(H3N2) and B (Table 2), and tended to be higher in chil-
ren than in adults. These estimates are in line with annual VE
stimates from other countries around the world in those years,
here VE was generally moderate [9–11]. In particular, these esti-
ates of VE are consistent with previous estimates from the US
ver the same time period [6–8] with a few exceptions of age and
eason-speciﬁc estimates. For example, in 2010–11, we  estimated
 low to moderate VE against inﬂuenza A(H3N2) in children aged 6
onths to 5 years of age, while Treanor et al. estimated a moderate
E of 66% (95% CI: 48%–78%) in children aged 6 months–8 years [6].
hen, in 2011–12, we estimated low VE against inﬂuenza for all ages
hich is consistent with the estimates by Ohmit et al. of a low to
oderate VE of 39% (95% CI: 23%–52%) against inﬂuenza A(H3N2)
7]. However, the estimated VE using comparable age groups in
010–11 was still lower in the IISP cohort than in Treanor et al. [6],
ut conﬁdence intervals overlapped, and VE in 2011–12 was very
imilar to that reported by Ohmit et al. [7]. A direct head-to-head
omparison of VE estimates from the IISP and the other studies is
nderway.
Annual inﬂuenza coverage for the United States was estimated
o be 42–43% in the general population during the years covered
y our study, and higher among children and the elderly [20].
oth the national estimates and IISP rely on self-reported vaccina-
ion, but vaccination coverage among IISP participants was lower.
mong children aged 6 months to 17 years vaccine coverage ranged
Season 2010
 All Influenza
−50% 0 50% 100%
6m−5yr
6−17yr
18−49yr
50yr+
All ages
Vaccine Ef fecti veness
Influenza A(H1N1)
−50% 0 50% 100%
6m−5yr
6−17yr
18−49yr
50yr+
All ages
Vaccine Ef fecti veness
6
6
18
A
Season 2011
 All Influenza
−50% 0 50% 100%
6m−5yr
6−17yr
18−49yr
50yr+
All ages
Vaccine Ef fecti veness
Influenza A(H1N1)
−50% 0 50% 100%
6m−5yr
6−17yr
18−49yr
50yr+
All ages
Vaccine Ef fecti veness
6
6
18
A
Season 2012
 All Influenza
−50% 0 50% 100%
6m−5yr
6−17yr
18−49yr
50yr+
All ages
Vaccine Ef fecti veness
Influenza A(H1N1)
−50% 0 50% 100%
6m−5yr
6−17yr
18−49yr
50yr+
All ages
Vaccine Ef fecti veness
6
6
18
A
ig. 2. Estimates of inﬂuenza vaccine effectiveness by type/subtype, age group and year.
stimation for adults aged >50 years was not possible in 2010–11 or for inﬂuenza A subtyp
 in 2011–12 or against A(H1N1) in 2012–13 due to small numbers of patients and low ce 34 (2016) 61–66
each season from 29% to 39%, and was substantially lower among
adults aged 18–49 years (18%–24%), but higher among patients
≥50 years (37%–48%). Because participation in this project was
conditional on seeking medical care for ARI, potential reasons for
the lower vaccination coverage in IISP include the overrepresen-
tation of inﬂuenza test positive individuals, the large proportion
of participants between the ages of 18–49 years, and an unclear
representation of insured persons.
The IISP has been shown to provide a successful alternate
approach to conducting population-based surveillance that is
enhanced by systematic molecular testing for respiratory viruses.
This simple platform has been useful for estimating the burden of
disease for inﬂuenza and other respiratory viruses [13–15], and
has demonstrated further utility for the estimation of VE. One of
the strengths of the present study is the large sample size, which
permitted precise estimation of VE in most age groups for the
predominant strains each season. Since this study was  based in
a sentinel surveillance system, it provides an efﬁcient approach to
routine annual estimation of VE. There are a few limitations worthy
of mention. First, vaccination history was  largely self-reported and
not validated, and this could have led to misclassiﬁcation bias, with
consequent underestimation of VE if the bias was non-differential.
We were unable to determine whether vaccinated children <9y of
age were fully vaccinated, i.e. if children with no prior experience of
inﬂuenza vaccine had received two  doses of vaccination at least 21
−2011
 Influenza A(H3N2)
−50% 0 50% 100%
m−5yr
−17yr
−49yr
50yr+
ll ages
Vaccine Ef fecti veness
 Influenza B
−50% 0 50% 100%
6m−5yr
6−17yr
18−49yr
50yr+
All ages
Vaccine Ef fecti veness
−2012
 Influenza A(H3N2)
−50% 0 50% 100%
m−5yr
−17yr
−49yr
50yr+
ll ages
Vaccine Ef fecti veness
 Influenza B
−50% 0 50% 100%
6m−5yr
6−17yr
18−49yr
50yr+
All ages
Vaccine Ef fecti veness
−2013
 Influenza A(H3N2)
−50% 0 50% 100%
m−5yr
−17yr
−49yr
50yr+
ll ages
Vaccine Ef fecti veness
 Influenza B
−50% 0 50% 100%
6m−5yr
6−17yr
18−49yr
50yr+
All ages
Vaccine Ef fecti veness
 95% conﬁdence intervals wider than 100 percentage points are not shown. Robust
es in 2011–12, and it was  not possible to estimate age-speciﬁc VE against inﬂuenza
irculation of the speciﬁc subtypes in these seasons.
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ays apart. Second, medical chart reviews were not conducted to
scertain underlying medical conditions due to resource intensive-
ess, which could be a confounder, also leading to the potential for
ias in estimation of VE. Third, there were several secondary anal-
ses that were not possible. Data were not collected on the type
f vaccine received, prohibiting analyses of VE for speciﬁc types of
accines, such as inactivated or live attenuated vaccines, and pos-
ible corresponding age differential VE. Finally, data were not col-
ected on prior vaccination history and we were not able to examine
he potential consequences of repeat vaccination on VE [12,21–24].
In conclusion, we have shown that estimation of VE using the
est-negative design and a routine surveillance network data is
easible. The data demonstrated that in each of the three seasons
tudied, inﬂuenza vaccination afforded protection against medi-
ally attended laboratory-conﬁrmed inﬂuenza virus infection for
he predominant circulating inﬂuenza strains. Given the national
nﬂuenza vaccination coverage was 42%–43% in the study years
nd the incidence of medical visits associated with laboratory-
onﬁrmed inﬂuenza was 7.0, 1.9 and 10.7 per 1000 persons in
he three study seasons respectively [15], the moderate VE esti-
ated here suggests that inﬂuenza vaccination had a substantial
ublic health impact. Moderate VE emphasizes the importance of
eveloping more immunogenic vaccines to provide higher pro-
ection in all ages, and the declining VE in older adults supports
he particular importance of more immunogenic vaccines in this
roup. Inﬂuenza vaccination provides the best protection against
nﬂuenza virus infection. The moderate effectiveness of inﬂuenza
accination across the three seasons in our study indicates the need
or complementary public health measures to further reduce the
urden of inﬂuenza.unding
This work was supported by the Council of State and Territo-
ial Epidemiologists (cooperative agreement 5U38HM000414-04
able A1
accine strain components in 2010–11, 2011–12 and 2012–13.
Virus 2010–11 2011–12 
A(H1N1) A/California/7/2009-like (H1N1) A/California/7/200
A(H3N2) A/Perth/16/2009-like (H3N2) A/Perth/16/2009-l
B  B/Brisbane/60/2008-like (B/Victoria lineage) B/Brisbane/60/200
able A2
omparison of patients testing positive for inﬂuenza A(H1N1), A(H3N2) and B viruses com
ncluded  during the three inﬂuenza seasons in our study period.a
Characteristic A(H1N1) (n = 550) 
Age group
6m–5yr 81 (14.7%) 
6–17yr 132 (24.0%) 
18–49yr 318 (57.8%) 
≥50yr 19 (3.5%) 
Unknown 0 (0) 
Sex
Male  261 (47.5%) 
Female 287 (52.2%) 
Unknown 2 (0.4%) 
Seasonal inﬂuenza vaccination history
Yes for that season (>2 weeks prior to onset) 52 (9.5%) 
No  reported vaccination for that season (>2 weeks prior to onset) 318 (57.8%) 
Reported as unknown 180 (32.7%) 
Inﬂuenza season
2010–11 415 (75.5%) 
2011–12 100 (18.2%) 
2012–13 35 (6.4%) 
a Of the patients positive for A(H1N1), 2 were also positive for A(H3N2) and 2 were also
atients with unsubtypeable inﬂuenza A virus infections were excluded from this table.e 34 (2016) 61–66 65
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.
2012–13
9-like (H1N1) A/California/7/2009-like (H1N1)
ike (H3N2) A/Victoria/361/2011-like (H3N2)
8-like (B/Victoria lineage) B/Wisconsin/1/2010-like (B/Yamagata lineage)
pared to patients testing negative for all inﬂuenza viruses, for the 10,650 patients
N (%) A(H3N2) (n = 1890) N (%) B (n = 1245) N (%) Negative (n = 6907) N (%)
349 (18.5%) 246 (19.8%) 2039 (29.5%)
578 (30.6%) 624 (50.1%) 1779 (25.8%)
711 (37.6%) 314 (25.2%) 2427 (35.1%)
250 (13.2%) 60 (4.8%) 658 (9.5%)
2 (0.1%) 1 (0.1%) 4 (0.1%)
877 (46.4%) 626 (50.3%) 3048 (44.1%)
993 (52.5%) 609 (48.9%) 3800 (55.0%)
20 (1.1%) 10 (0.8%) 59 (0.9%)
416 (22.0%) 215 (17.3%) 2097 (30.4%)
1155 (61.1%) 696 (55.9%) 3367 (48.7%)
319 (16.9%) 334 (26.8%) 1443 (20.9%)
478 (25.3%) 511 (41.0%) 2784 (40.3%)
293 (15.5%) 57 (4.6%) 1692 (24.5%)
1119 (59.2%) 677 (54.4%) 2431 (35.2%)
 positive for B, while 11 patients were positive for A(H3N2) and B. 73/10,650 (0.7%)
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